The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Change in tumor lysis syndrome risk after lead-in treatment in a phase 1b/2 study of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia.
 
Kerry Anne Rogers
Research Funding - Genentech
 
Ying Huang
No Relationships to Disclose
 
Amy S. Ruppert
No Relationships to Disclose
 
Todd Civils
No Relationships to Disclose
 
Subhashish Das
No Relationships to Disclose
 
Christin Fedor
No Relationships to Disclose
 
W. Thomas Whitlow
No Relationships to Disclose
 
Farrukh T Awan
Consulting or Advisory Role - Abbvie; Gilead Sciences; Janssen
Research Funding - Pharmacyclics
 
Kami J. Maddocks
Honoraria - Bristol-Myers Squibb; Janssen; Pharmacyclics; Seagen
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Pharmacyclics; Seagen
Research Funding - Merck; Pharmacyclics
 
Jennifer Ann Woyach
Honoraria - Janssen
Consulting or Advisory Role - Janssen
Research Funding - Abbvie; Karyopharm Therapeutics; MorphoSys
 
Jeffrey Alan Jones
Employment - Celgene
Stock and Other Ownership Interests - Celgene
Consulting or Advisory Role - Abbvie; Acerta Pharma; Alexion Pharmaceuticals; Gilead Sciences; Janssen Oncology; Pharmacyclics
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Genentech/Abbvie (Inst); Gilead Sciences (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Pharmacyclics (Inst); Sunesis Pharmaceuticals (Inst)
 
John C. Byrd
Consulting or Advisory Role - Acerta Pharma
Research Funding - Acerta Pharma (Inst); Genentech (Inst); Janssen (Inst); Pharmacyclics (Inst)